Astellas pulls out of deal with Theravance
Japanese drug major Astellas Pharma (TYO: 4503) says it has exercised its right to terminate the global license, development and commercialization agreement with US firm Theravance (Nasdaq: THRX) for Vibativ (telavancin) for injection, a bactericidal, once-daily lipoglycopeptide injectable antibiotic discovered by Theravance.
Theravance, which received an upfront payment of $65 million and accrued regulatory milestone of $156 million under the deal between the two companies (The Pharma Letter December 12, 2005) is evaluating global commercialization alternatives for Vibativ either alone or with partners.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze